REV-ERB raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-14 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Milan Mrksich (born 15 August 1968) is an American chemist. He is the Henry Wade Rogers Professor at Northwestern University with appointments in chemistry, biomedical engineering and cell & developmental biology. He also served as both the founding director of the Center for Synthetic Biology and as an associate director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern. Mrksich also served as the Vice President for Research of Northwestern University. His research involves the chemistry and synthesis of surfaces that contact biological environments. His laboratory has pioneered several technologies, including strategies to integrate living cells with microelectronic devices, methods to enable high throughput assays for drug discovery, and approaches to making synthetic fusion proteins for applications as therapeutics. Most notably, he developed the SAMDI-MS biochip technology that allows for high-throughput quantification of surface-based biochemical assays using MALDI mass spectrometry. Through SAMDI-MS, Mrksich has become a leader in using label-free technology for drug discovery, founding the company SAMDI Tech in 2011 that primarily serves global pharmaceutical companies. His work has been described in over 240 publications (h-index 98), 500 invited talks, and 18 patents.
Urinary tract infection Skin infection Respiratory tract infection Odontogenic infection (an infection that originates within a tooth or in the closely surrounding tissues) Vaginal infections Intra-amniotic infection In addition, locations of inflammation where infection is the most common cause include pneumonia, meningitis and salpingitis.
Amines, alkyl and aryl alike, are organized into three subcategories (see table) based on the number of carbon atoms adjacent to the nitrogen (how many hydrogen atoms of the ammonia molecule are replaced by hydrocarbon groups): Primary (1°) amines—Primary amines arise when one of three hydrogen atoms in ammonia is replaced by an alkyl or aromatic group. Important primary alkyl amines include methylamine, most amino acids, and the buffering agent tris, while primary aromatic amines include aniline. Secondary (2°) amines—Secondary amines have two organic substituents (alkyl, aryl or both) bound to the nitrogen together with one hydrogen. Important representatives include dimethylamine, while an example of an aromatic amine would be diphenylamine. Tertiary (3°) amines—In tertiary amines, nitrogen has three organic substituents. Examples include trimethylamine, which has a distinctively fishy smell, and EDTA. A fourth subcategory is determined by the connectivity of the substituents attached to the nitrogen:
In chemical analysis, capillary electrochromatography (CEC) is a chromatographic technique in which the mobile phase is driven through the chromatographic bed by electro-osmosis. Capillary electrochromatography is a combination of two analytical techniques, high-performance liquid chromatography and capillary electrophoresis. Capillary electrophoresis aims to separate analytes on the basis of their mass-to-charge ratio by passing a high voltage across ends of a capillary tube, which is filled with the analyte. High-performance liquid chromatography separates analytes by passing them, under high pressure, through a column filled with stationary phase. The interactions between the analytes and the stationary phase and mobile phase lead to the separation of the analytes. In capillary electrochromatography capillaries, packed with HPLC stationary phase, are subjected to a high voltage. Separation is achieved by electrophoretic migration of solutes and differential partitioning.
Sources: en.wikipedia.org
The science of collecting and analyzing biologic or health data using statistical methods. Biometry may be used to help learn the possible causes of a disease in a certain group of people. Also called biostatistics and biometrics. (NCI) Biostatistics
=== Prosecution === In his opening statement, prosecutor Brian Leveson portrayed the Wests as sadistic sex-obsessed murderers, terming the bodies discovered at Cromwell Street and Midland Road "secrets more terrible than words can express ... [The victims'] last moments on earth were as objects of the sexual depravity of this woman and her husband." He pointed out that Fred had been incarcerated when Charmaine was killed, claimed that Fred and Rose had each learned from their mistake in allowing Owens to live, and said that the gag on victim Thérèse Siegenthaler evinced a "feminine" touch—a scarf tied in a bow. Leveson promised to demonstrate Rose's controlling and sexually sadistic character, as well as her efforts to deflect suspicion about the disappearance of their victims. Prosecution witnesses included Cromwell Street lodgers, victims' relatives, Rose's mother, Daisy, and sister, Glenys, and surviving victims including Kathryn Halliday (a former lover of Fred and Rose), Owens, Anne Marie and a "Miss A" (who had been sexually assaulted at age 14 by Fred and Rose in 1977 and who described Rose as the more aggressive perpetrator of the two). Neighbours described Charmaine's 1971 disappearance while Fred was imprisoned and Rose's casual indifference to Heather's disappearance. Rose's counsel, Dick Ferguson, tried to discredit prosecution witnesses as either having financially exploited their connection to the case or being motivated by grudges.
=== Administrative history === Wilmslow was an ancient parish in the Macclesfield Hundred of Cheshire. The parish was subdivided into four townships, called Bollin Fee, Chorley, Fulshaw, and Pownall Fee. The town centre and the parish church of St Bartholomew's lay in the Bollin Fee township. From the 17th century onwards, parishes were gradually given various civil functions under the poor laws, in addition to their original ecclesiastical functions. In some cases, including Wilmslow, the civil functions were exercised by each township separately rather than the parish as a whole. In 1866, the legal definition of 'parish' was changed to be the areas used for administering the poor laws, and so the townships each became separate civil parishes, which therefore diverged from the ecclesiastical parish. In 1862, a Chorley local government district was created, governed by an elected local board. The district covered the eastern part of the Chorley township, plus small adjoining parts of the Bollin Fee and Fulshaw townships. The Chorley district was renamed Alderley Edge in 1894. In 1878, a separate Wilmslow local government district was created covering the remainder of Bollin Fee and Fulshaw, plus Pownall Fee apart from the area north of the River Bollin and River Dean; the excluded area north of the rivers contained the hamlet of Styal. Local government districts were reconstituted as urban districts under the Local Government Act 1894.
That evening, the Lebanese Armed Forces (LAF) and UNIFIL withdrew from the Israeli-Lebanese border to the north to a distance of 5 kilometres (3.1 mi; 2.7 nmi) from the border, while the IDF designated the settlements of Metula, Misgav Am and Kfar Giladi as closed military areas. Israeli troops amassed on the border in southern Lebanon, with Israel stating that they were preparing for a limited ground invasion.
EPA proposed a legal limit of a maximum of 3.5 millisieverts (350 millirem) each annually to local individuals after 10,000 years, which would be up to several percent of the exposure currently received by some populations in the highest natural background regions on Earth, though the United States Department of Energy (DOE) predicted that received dose would be much below that limit. Over a timeframe of thousands of years, after the most active short half-life radioisotopes decayed, burying U.S. nuclear waste would increase the radioactivity in the top 2000 feet of rock and soil in the United States (10 million km2) by approximately 1 part in 10 million over the cumulative amount of natural radioisotopes in such a volume, but the vicinity of the site would have a far higher concentration of artificial radioisotopes underground than such an average.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.